RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming November Conferences

Repligen Corporation to Present at Upcoming November Conferences

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming investor conferences.

  • The UBS Global Healthcare Conference, being held November 10 – 12 in Palm Beach Gardens, FL. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion at 11:00 a.m. ET on Monday, November 10.
  • The Stifel Healthcare Conference, being held November 11 – 13 in New York. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion at 10:00 a.m. ET on Tuesday, November 11.
  • The Wolfe Research Healthcare Conference, being held November 17 – 19 in New York. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion at 12:40 p.m. ET on Tuesday, November 18.
  • The Jefferies Global Healthcare Conference, being held November 18 – 20 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion at 8:30 a.m. ET/1:30 p.m. Greenwich Mean Time on Tuesday, November 18.
  • The Stephens Annual Investment Conference, being held November 18 – 20 in Nashville. Jason Garland, Chief Financial Officer, will participate in a series of one-on-one meetings with investors on Wednesday, November 19.

A live webcast of the conference presentations will be accessible through Repligen’s website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at , and follow us on .

Repligen Contact:

Jacob Johnson

VP, Investor Relations

781-419-0204

 





EN
04/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE

Repligen Corporation to Present at Upcoming November Conferences

Repligen Corporation to Present at Upcoming November Conferences WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming investor conferences. The UBS Global Healthcare Conference, being held November 10 – 12 in Palm Beach Gardens, FL. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion at 11:00 a.m. ET on Monday, November 10.The Stifel Healthcare Conference, being held November 11 – 13 in New York....

 PRESS RELEASE

Repligen Reports Third Quarter 2025 Financial Results and Updates Full...

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, ...

 PRESS RELEASE

Repligen to Report Third Quarter 2025 Financial Results

Repligen to Report Third Quarter 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025. The conference ca...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

Repligen Corp: 1 director

A director at Repligen Corp sold after exercising options/sold 29,111 shares at 120.518USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch